Hemostemix Inc.: Hemostemix to Combine ACP-01 with Dr. James Shapiro's Islet Cells to Treat Type 1 Diabetes

Calgary, Alberta--(Newsfile Corp. - January 11, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce it has signed a contract with Dr.

Related Keywords

Canada ,Canadian ,Thomas Smeenk ,James Shapiro ,Fraser Henderson ,Royal Society Of Canada ,University Of Alberta ,Royal College Of Surgeons England ,Regulation Service Provider ,Department Of Surgery ,World Economic Forum Technology Pioneer Award ,Hemostemix Inc ,Canada Research Council ,Alberta Newsfile Corp ,Venture Exchange ,England Journal ,Hunterian Medal ,Royal College ,Gold Medal ,Governor General ,Nature Biotechnology ,Royal Society ,Transplantation Surgery ,Ischemic Cardiomyopathy ,Stem Cell Treatment ,Regulating Stem Cells ,Vitro Techniques ,Stem Cells ,Neural Lineage ,Automated Cell ,Looking Information ,Common Shares ,Hemostemix ,Ombine ,Games ,Shapiro ,Islet ,Cells ,Treat ,Type ,Diabetes ,